Clinical Trial: Phase 2a, Randomized, Open-Label Study of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Advanced Unresectable Hepatocellular Carcinoma

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07175441) titled 'Phase 2a, Randomized, Open-Label Study of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Advanced Unresectable Hepatocellular Carcinoma' on Sept. 09.

Brief Summary: RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelim...